Expand TNXP Menu
TNXP MENU

TNXP Latest Press Releases

-- September 2, 2026 --

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference Globe Newswire 7:00 AM

-- August 10, 2026 --

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights Globe Newswire 7:00 AM

-- August 5, 2026 --

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 3, 2026 --

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. Globe Newswire 7:00 AM

-- July 27, 2026 --

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 Globe Newswire 7:00 AM

-- July 15, 2026 --

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models Globe Newswire 9:05 AM

-- July 13, 2026 --

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA Globe Newswire 7:00 AM

-- June 29, 2026 --

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) Globe Newswire 7:25 AM

-- June 11, 2026 --

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 Globe Newswire 7:00 AM

-- June 8, 2026 --

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA, Expanding Total Commercial Coverage to ~52 Million U.S. Lives Globe Newswire 7:00 AM

-- May 28, 2026 --

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Globe Newswire 4:30 PM

-- May 27, 2026 --

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology Globe Newswire 7:00 AM

-- May 26, 2026 --

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting Globe Newswire 7:00 AM

-- May 14, 2026 --

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 Globe Newswire 7:00 AM

-- May 12, 2026 --

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May Globe Newswire 4:30 PM

-- May 11, 2026 --

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights Globe Newswire 4:30 PM

-- May 6, 2026 --

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA, Providing Access for ~35 Million U.S. Patients Globe Newswire 7:00 AM

-- April 29, 2026 --

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University Globe Newswire 7:00 AM

-- April 23, 2026 --

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 Globe Newswire 7:00 AM

-- April 15, 2026 --

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes